Metavia Inc (MTVA) Stock Price, Quote & News

Company Profile

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomod...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 702 9600

Website: www.metaviatx.com

Address:

545 Concord Avenue, Suite 210, Cambridge, United States

NebulaNovice Dec. 24 at 10:22 AM

$MTVA Expectations are now anchored to how internal discipline offsets macro and competitive headwinds. Momentum requires evidence, not projections.

0 · Reply

OfficialStocktwitsUser Dec. 23 at 6:07 AM

$MTVA RSI: 61.51, MACD: -0.0404 Vol: 1.07, MA20: 8.43, MA50: 9.33 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Motorhhead Dec. 23 at 12:32 AM

$VTGN was a "bottom play" according to this thing. $MTVA $SIDU was down 33%. I have to hand it to this thing as it's the best short indicator on ST

0 · Reply

SPYmyQQQ Dec. 22 at 10:26 PM

🎯 Target Hit 🏁 📨 From Dec 17, 2025 💊 $MTVA 💵 Entry: $8.1400 ✅ Ext: $9.6785 💰 P/L: +18.90% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

jeremy50641 Dec. 22 at 9:28 PM

$MTVA is data still coming by EOY?

1 · Reply

hbkstockislife Dec. 22 at 8:48 PM

$MTVA let data come ..These 20 cents profit penny flippers will chase

0 · Reply

JohnTrack Dec. 22 at 8:34 PM

$MTVA watching for continuation!

0 · Reply

Geo1313 Dec. 22 at 5:20 PM

$VTGN $SIDU $MTVA $VTGN

0 · Reply

beppels Dec. 22 at 4:29 PM

$VTGN $SIDU, 1.38 to 2.5 $MTVA, 8.3 to 9.5 $VTGN, 0.76 to 0.84! 3 out of 3, good day!

0 · Reply

hbkstockislife Dec. 22 at 4:23 PM

$MTVA Data anytime ..

0 · Reply

MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement

Dec 2, 2025, 8:45 AM EST - 23 days ago

MetaVia Inc. Announces 1-for-11 Reverse Stock Split

Nov 7, 2025, 8:31 AM EST - 6 weeks ago

MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025

Nov 6, 2025, 8:31 AM EST - 7 weeks ago

MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 4, 2025, 4:01 PM EST - 7 weeks ago

MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025

Oct 27, 2025, 8:31 AM EDT - 2 months ago

MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting

Oct 20, 2025, 8:31 AM EDT - 2 months ago

MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025

Oct 14, 2025, 8:31 AM EDT - 2 months ago

MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference

Aug 26, 2025, 8:31 AM EDT - 4 months ago

MetaVia to Present at Upcoming Investor and Industry Conferences

Aug 7, 2025, 8:31 AM EDT - 5 months ago

MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 8:31 AM EDT - 5 months ago

MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient

Aug 4, 2025, 8:31 AM EDT - 5 months ago

MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241

Jul 9, 2025, 8:31 AM EDT - 6 months ago

MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose

Jun 21, 2025, 9:00 AM EDT - 6 months ago

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session

Jun 10, 2025, 8:31 AM EDT - 7 months ago

MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th

Jun 4, 2025, 8:31 AM EDT - 7 months ago

MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions

May 14, 2025, 4:05 PM EDT - 8 months ago

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 9, 2025, 8:01 AM EDT - 8 months ago

MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

May 7, 2025, 2:00 AM EDT - 8 months ago

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025

Apr 23, 2025, 8:31 AM EDT - 8 months ago

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025

Apr 22, 2025, 8:31 AM EDT - 8 months ago

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential

Apr 15, 2025, 7:01 AM EDT - 9 months ago

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

Mar 20, 2025, 7:31 AM EDT - 10 months ago

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

Jan 10, 2025, 8:05 AM EST - 1 year ago

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

Nov 18, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

Nov 13, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

Nov 7, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 4, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Oct 1, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

Sep 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Sep 3, 2024, 8:01 AM EDT - 1 year ago

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Aug 6, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity

Jul 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01

Jul 11, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July

Jun 26, 2024, 9:06 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Jun 25, 2024, 5:08 PM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 24, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 22, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models

May 22, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone

May 9, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

Apr 17, 2024, 8:05 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Apr 1, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Mar 28, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

Mar 13, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Mar 4, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

Feb 29, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Feb 12, 2024, 8:01 AM EST - 2 years ago

NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference

NebulaNovice Dec. 24 at 10:22 AM

$MTVA Expectations are now anchored to how internal discipline offsets macro and competitive headwinds. Momentum requires evidence, not projections.

0 · Reply

OfficialStocktwitsUser Dec. 23 at 6:07 AM

0 · Reply

Motorhhead Dec. 23 at 12:32 AM

$VTGN was a "bottom play" according to this thing. $MTVA $SIDU was down 33%. I have to hand it to this thing as it's the best short indicator on ST

0 · Reply

SPYmyQQQ Dec. 22 at 10:26 PM

🎯 Target Hit 🏁 📨 From Dec 17, 2025 💊 $MTVA 💵 Entry: $8.1400 ✅ Ext: $9.6785 💰 P/L: +18.90% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

jeremy50641 Dec. 22 at 9:28 PM

$MTVA is data still coming by EOY?

1 · Reply

hbkstockislife Dec. 22 at 8:48 PM

$MTVA let data come ..These 20 cents profit penny flippers will chase

0 · Reply

JohnTrack Dec. 22 at 8:34 PM

$MTVA watching for continuation!

0 · Reply

Geo1313 Dec. 22 at 5:20 PM

$VTGN $SIDU $MTVA $VTGN

0 · Reply

beppels Dec. 22 at 4:29 PM

$VTGN $SIDU, 1.38 to 2.5 $MTVA, 8.3 to 9.5 $VTGN, 0.76 to 0.84! 3 out of 3, good day!

0 · Reply

hbkstockislife Dec. 22 at 4:23 PM

$MTVA Data anytime ..

0 · Reply

JohnTrack Dec. 22 at 3:44 PM

$MTVA Regains Compliance with Nasdaq Minimum Bid Price Requirement https://www.rapidticker.com/news/mtva-metavia-regains-compliance-with-nasdaq-596b25

0 · Reply

TCSVCD Dec. 22 at 1:35 PM

$MTVA https://www.stocktitan.net/news/MTVA/

0 · Reply

beppels Dec. 22 at 7:39 AM

$VTGN BEPPELS WL 22.12.: - $VTGN, 0.76 $, has 100 % room to net cash of 1.54 $ per share, bottom play! ✅ - $MTVA, 8.3 $, 530 k float, top-line data due any day now! ✅ - $SIDU, 1.38 $, 35 mln float, space play, ah runner on friday! ✅ Also watch $IMG, $SUGP, arbk 👀 🔥 👀

1 · Reply

smartmoney43 Dec. 19 at 6:05 PM

$MTVA watching closely 👀

0 · Reply

Ren_Stimpy Dec. 16 at 3:18 PM

Sold all my favorite biotech shares!! $MTVA $BEAT $CATX $GUTS for a much safer stock that has 5x stock price potential plus 14% dividends!! $IIPR Cannabis company has a proven profitable business model!! Trump is reclassifying cannabis to make cannabis legal in the U.S.A.!! Get in while it’s still cheap!!

1 · Reply

aletz Dec. 15 at 2:26 PM

$MTVA https://www.biostockinfo.com/biotech-catalyst-ai-scanner-december-wk3/ My AI scanner has been picking MTVA for 4 weeks in a row, low float has made it an easy target for pumpers and I am not too sure if it has edge over other big players in the obesity sector.

0 · Reply

Kertzi Dec. 15 at 9:30 AM

$MTVA Beware of the lies that @XMANLUKE & pumpers club share about MetaVia and Pfizer... The only connection between the two is that MetaVia originally (2018) licensed the now-discontinued, inactive drug Gemcabene. DA-1241 and DA-1726 have nothing to do with Pfizer!

1 · Reply

XMANLUKE Dec. 15 at 12:27 AM

$MTVA Zero Debt, 14+ mil. In cash , EPS projected 12.5% growth per Annum. License agreement with Pfizer. I'm Bullish

0 · Reply

BioRich Dec. 13 at 1:59 PM

$ALT Congrats to $CMND for their publication for AUD; yet another competitor for $ALT. Currently halted pending news. We've seen 100% gains in a day with this one. Could see an R/S to get it on the radar of bigger institutions, but that's often a solid strategic move (ref. $MTVA and $TNXP). Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (MORE) money. Cheers! $XBI https://www.clearmindmedicine.com/news-release/clearmind-medicines-meai-spotlighted-in-prestigious-review-leading-experts-affirm-transformative-potential-for-alcohol-use-disorder-treatment

0 · Reply

Joby099 Dec. 12 at 9:45 AM

$MTVA

0 · Reply

Kertzi Dec. 12 at 3:42 AM

@ZacksSCR crashed the $MTVA target price from $250 ($23 pre-split) to $90 ($8) — a 65% cut. This haircut signals expectations of massive upcoming dilution, with the share count projected to explode from roughly 2 million to nearly 100 million! EXTREMELY BEARISH!

1 · Reply

Joby099 Dec. 11 at 11:51 PM

$MTVA

0 · Reply

Market Cap	21.11M
Revenue (ttm)	0.00
Net Income (ttm)	-27.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	22,800
Avg Vol	230,447
Day's Range	N/A - N/A
Shares Out	2.20M
Stochastic %K	89%
Beta	0.29
Analysts	Strong Sell
Price Target	$72.50